Sandbox:Fahimeh: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
|- style="background: #4479BA; color: #FFFFFF; text-align: center;" | |- style="background: #4479BA; color: #FFFFFF; text-align: center;" | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;|Diseases | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;|Diseases | ||
| | |||
| colspan="6" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;|'''Clinical manifestations''' | | colspan="6" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;|'''Clinical manifestations''' | ||
| | | | ||
| Line 10: | Line 11: | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;|Additional findings | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;|Additional findings | ||
|- | |- | ||
| rowspan="3" |History | |||
| colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;|'''Symptoms''' | | colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;|'''Symptoms''' | ||
! colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination | ! colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination | ||
| Line 32: | Line 34: | ||
|- | |- | ||
|- style="background: #4479BA; color: #FFFFFF; text-align: center;" | |- style="background: #4479BA; color: #FFFFFF; text-align: center;" | ||
! colspan=" | ! colspan="18" |Constrictive pericarditis | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Tuberculosis | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Tuberculosis | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 53: | Line 56: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Idiopathic/Viral | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Idiopathic/Viral | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 71: | Line 75: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Post cardiac surgery | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Post cardiac surgery | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 89: | Line 94: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Post radiation | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Post radiation | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 107: | Line 113: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Connective tissue disease | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Connective tissue disease | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 125: | Line 132: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Malignancy | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Malignancy | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 143: | Line 151: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Mesothelioma]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Mesothelioma]] | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 161: | Line 170: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Chronic [[renal failure]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Chronic [[renal failure]] | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 179: | Line 189: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Asbestosis | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Asbestosis | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 196: | Line 207: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- style="background: #4479BA; color: #FFFFFF; text-align: center;" | |- style="background: #4479BA; color: #FFFFFF; text-align: center;" | ||
! colspan=" | ! colspan="18" |Restrictive cardiomyopathy | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Amyloidosis | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Amyloidosis | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 217: | Line 229: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Sarcoidosis | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Sarcoidosis | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 235: | Line 248: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Hemochromatosis | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Hemochromatosis | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 253: | Line 267: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Sclerodema | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Sclerodema | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 271: | Line 286: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Endomyocardial fibrosis | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Endomyocardial fibrosis | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 289: | Line 305: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Carcinoid heart disease | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Carcinoid heart disease | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 307: | Line 324: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Post radiation | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Post radiation | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 325: | Line 343: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Diabetic cardiomyopathy | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Diabetic cardiomyopathy | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 343: | Line 362: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Hurler | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Hurler | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 361: | Line 381: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Gaucher | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Gaucher | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 379: | Line 400: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Fabry | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Fabry | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 397: | Line 419: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Wegener | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Wegener | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| Line 415: | Line 438: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Metastatic malignancies | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Metastatic malignancies | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Revision as of 23:37, 27 February 2020
| Diseases | Clinical manifestations | Para-clinical findings | Gold standard | Additional findings | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| History | Symptoms | Physical examination | |||||||||||||||
| Lab Findings | Imaging | Histopathology | |||||||||||||||
| Chest pain | Fever | Cough | Edema/Ascites | JVP | Heart/Lung sounds | Hepatosplenomegaly | Lab 1 | Lab 2 | Lab 3 | CT Scan | MRI | Echo/Sono | |||||
| Constrictive pericarditis | |||||||||||||||||
| Tuberculosis | |||||||||||||||||
| Idiopathic/Viral | |||||||||||||||||
| Post cardiac surgery | |||||||||||||||||
| Post radiation | |||||||||||||||||
| Connective tissue disease | |||||||||||||||||
| Malignancy | |||||||||||||||||
| Mesothelioma | |||||||||||||||||
| Chronic renal failure | |||||||||||||||||
| Asbestosis | |||||||||||||||||
| Restrictive cardiomyopathy | |||||||||||||||||
| Amyloidosis | |||||||||||||||||
| Sarcoidosis | |||||||||||||||||
| Hemochromatosis | |||||||||||||||||
| Sclerodema | |||||||||||||||||
| Endomyocardial fibrosis | |||||||||||||||||
| Carcinoid heart disease | |||||||||||||||||
| Post radiation | |||||||||||||||||
| Diabetic cardiomyopathy | |||||||||||||||||
| Hurler | |||||||||||||||||
| Gaucher | |||||||||||||||||
| Fabry | |||||||||||||||||
| Wegener | |||||||||||||||||
| Metastatic malignancies | |||||||||||||||||